TABLE 1.
Baseline characteristics
| Transplant |
Total control |
p value | Matched control |
p value | |
|---|---|---|---|---|---|
| N = 82 | N = 10 356 | N = 1625 | |||
| Age, mean ± SD | 61.8 ± 11.7 | 64.9 ± 16.2 | .081 | 62.7 ± 11.5 | .50 |
| Gender | |||||
| Male | 56 (68.3%) | 6151 (59.4%) | .11 | 1117 (68.7%) | .93 |
| Race/Ethnicity | |||||
| Non-hispanic white | 19 (23.2%) | 3521 (34%) | .043 | 477 (29.4%) | .34 |
| Hispanic | 17 (20.7%) | 2185 (21.1%) | 335 (20.6%) | ||
| Non-Hispanic black | 26 (31.7%) | 2075 (20%) | 385 (23.7%) | ||
| Other | 17 (20.7%) | 1824 (17.6%) | 312 (19.2%) | ||
| Unknown | 3 (3.7%) | 751 (7.3%) | 116 (7.1%) | ||
| BMI | |||||
| 18.5–29.9 | 51 (62.2%) | 5486 (53%) | .042 | 783 (48.2%) | <.001 |
| <18.5 | 4 (4.9%) | 193 (1.9%) | 9 (0.6%) | ||
| ≥30.0 | 22 (26.8%) | 3544 (34.2%) | 684 (42.1%) | ||
| Unknown | 5 (6.1%) | 1133 (10.9%) | 149 (9.2%) | ||
| Diabetes | 51 (62.2%) | 3688 (35.6%) | <.001 | 1005 (61.8%) | .95 |
| Hypertension | 69 (84.1%) | 6098 (58.9%) | <.001 | 1365 (84%) | .97 |
| PVD/PAD | 3 (3.7%) | 238 (2.3%) | .44 | 59 (3.6%) | .99 |
| Heart failure | 10 (12.2%) | 818 (7.9%) | .15 | 163 (10%) | .51 |
| CAD | 20 (24.4%) | 1305 (12.6%) | .004 | 335 (20.6%) | .40 |
| Asthma | 3 (3.7%) | 869 (8.4%) | .12 | 154 (9.5%) | .099 |
| COPD | 2 (2.4%) | 640 (6.2%) | .16 | 117 (7.2%) | .96 |
| Initial serum creatinine (mg/dL) | 1.8 (1.3–2.9) | 1 (0.8–1.4) | <.001 | ||
| GFR (mL/min/1.732) | |||||
| ≥ 60 | 12 (14.6%) | 6359 (61.4%) | <.001 | 964 (59.3%) | <.001 |
| 30–59 | 39 (47.6%) | 2630 (25.4%) | 447 (27.5%) | ||
| <30 | 31 (37.8%) | 1346 (13%) | 214 (13.2%) | ||
| Missing | .(0%) | 21 (0.2%) | |||
| Tobacco Status | |||||
| Smoker (current or former) | 15 (18.3%) | 2055 (19.8%) | .93 | 370 (22.8%) | .64 |
| Never smoked | 62 (75.6%) | 7646 (73.8%) | 1165 (71.7%) | ||
| Unknown | 5 (6.1%) | 655 (6.3%) | 90 (5.5%) | ||
| RAASi | 17 (22.4%) | 2969 (31.5%) | .11 | 740 (48.8%) | <.001 |
| Admission hospital | |||||
| Nontransplant center | 45 (54.9%) | 8468 (81.8%) | <.001 | 1327 (81.7%) | <.001 |
| Transplant center | 37 (45.1%) | 1888 (18.2%) | 298 (18.3%) | ||
| Organ type | |||||
| Kidney | 69 (84.2%) | ||||
| Heart | 6 (7.3%) | ||||
| Liver | 3 (3.7%) | ||||
| Lung | 1 (1.2%) | ||||
| Kidney/Pancreas | 2 (2.4%) | ||||
| Kidney/Liver | 1 (1.2%) | ||||
| Induction agent | |||||
| Antithymocyte globulin (rabbit) | 8 (9.8%) | ||||
| Basiliximab | 14 (17%) | ||||
| None | 4 (4.9%) | ||||
| Unknown | 56 (68.3) | ||||
| Calcineurin inhibitor | 71 (86.6%) | ||||
| Mycophenolate | 65 (79.3%) | ||||
| Prednisone | 55 (67.1%) | ||||
| Belatacept | 2 (2.4%) | ||||
| mTOR inhibitor | 3 (3.7%) | ||||
| Immunosuppression reduced | 66 (80.5%) | ||||
| Transplant to COVID–19 infection, days (median [IQR]) | 2592 (599–4837) | ||||
All data presented as n (%), unless otherwise noted.
Cardiovascular disease defined as coronary artery disease, peripheral vascular disease, or heart failure.
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; mTOR, mammalian target of rapamycin; PVD/PAD, peripheral vascular disease/peripheral artery disease; RAASi, renin-angiotensin-aldosterone receptor inhibitor.